Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions
Study Details
Study Description
Brief Summary
In collaboration with Raffles Medical Group, we will be recruiting 500 patients and following them for the next 3-12 months to see whether pharmacogenomics information provided in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Pre-emptive genotyping provides relevant genomic data to physicians to facilitate prescribing and to facilitate checking of prescriptions by pharmacists to ensure drug safety and efficacy. This essential information should be incorporated into electronic healthcare systems and should be readily available. The effectiveness of pre-emptive genotyping to reduce adverse drug reactions (ADRs) is unknown in Singapore. Hence, this study is designed to evaluate whether it is feasible to implement large scale pre-emptive genotyping program at a hospital in Singapore and aim to integrate genomic medicine into clinical practice to improve drug safety and efficacy.
This study involves the testing of feasibility of pharmacogenomic genotyping in hospitals whereby our pharmacogenomics panel tests for 5 genes (CYP2D6, CYP2C9, CYP2C19, SLCO1B1 and HLA-B*58:01) which influences patient's response to more than 165 medications. Reports will be generated for all drugs that have been reported to be in CPIC Level A/B of association with the genes/haplotypes. The patients who are given these tests for free are recommended due to having experienced at least one of the diseases in our list or is at a risk of developing them.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| RMG Patients
|
Diagnostic Test: Pharmacogenomics Testing
To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
|
Outcome Measures
Primary Outcome Measures
- Turnaround time of genotype result, compared to expected [6 months]
- Overall satisfaction of patient [0 months]
Via survey upon recruitment
- Overall satisfaction of patient [3 month]
Via survey at month 3 of the study
- Overall satisfaction of patient [12 months]
Via survey at month 12 of the study
- Overall satisfaction of site principal investigators [6 months]
Via survey done at month 6 of the study
- Overall satisfaction of prescribing physicians [12 months]
Via survey done at month 12 of the study
- Prevalence of clinically actionable genotypes [12 months]
The number of patients receiving recommendations that includes a certain follow up action which includes monitoring, change of dosing or change of prescription.
- Recommendation acceptance rate [12 months]
Defined by: (1) Number of physicians who are interested to consider pharmacogenomics information to guide prescription, measured by click-through rate of Pharmacogenomics Access Button; (2) Number of changes made to the medications post-PGx testing; (3) Data obtained from satisfaction survey for prescribing physicians
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients who experienced at least one of the following diseases, or is at risk of developing them:
-
Diabetes Mellitus
-
Hypertension
-
Hyperlipidaemia
-
Ischaemic Heart Disease
-
Stroke
-
Osteoarthritis
-
Rheumatoid Arthritis
-
Gout
-
Anxiety
-
Major Depression
Exclusion Criteria:
- Below ages 21 and above ages 65
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Raffles Hospital | Singapore | Singapore | 188770 |
Sponsors and Collaborators
- Nalagenetics Pte Ltd
Investigators
- Principal Investigator: Melvin Wong, Dr, Raffles Medical Group
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SG-RMG-01-20190401